Pfizer (PFE) and BioNTech’s (BNTX) COVID-19 vaccine is proving effective six months after the second dose, according to an ongoing analysis of the Phase 3 trial participants.
The vaccine showed 91.3% efficacy against COVID-19, slightly lower than the original 95% seen in Phase 3 trials.
The data, from 12,000 of the more than 44,000 adults in the trial, is a result of observations from seven days through six months after the second dose was received.
The two companies announced the results in a…
Source link
